NasdaqCM - Nasdaq Real Time Price USD

DiaMedica Therapeutics Inc. (DMAC)

9.25 -0.27 (-2.84%)

At close: October 30 at 4:00:01 PM EDT

9.25 -0.02 (-0.27%)

After hours: October 30 at 4:00:02 PM EDT

Trade DMAC on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for DMAC

Previous Close 9.52
Open 9.39
Bid 6.74 x 200
Ask 11.86 x 200
Day's Range 9.16 - 9.54
52 Week Range 5.24 - 10.42
Volume 174,646
Avg. Volume 185,279
Market Cap (intraday) 498.813M
Beta (5Y Monthly) 0.91
PE Ratio (TTM) --
EPS (TTM) -0.72
Earnings Date (est.) Nov 11, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 15.50
Motley Fool Rating Bearish

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

www.diamedica.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DMAC

16.21%

S&P 500 (^GSPC)

10.73%

1-Year Return

DMAC

32.14%

S&P 500 (^GSPC)

11.11%

3-Year Return

DMAC

330.23%

S&P 500 (^GSPC)

81.91%

5-Year Return

DMAC

134.18%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -14.13M

Profit Margin 0.00%

FY25

FY26

-10M

-5M

0.0%

Analyst Price Targets

11.00

15.50 Average

9.25 Current

25.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 8/11/2026

Analyst HC Wainwright & Co.

Rating Action Reiterates

Rating Buy

Price Action Maintains

Price Target 12 -> 12

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-64.12%
Return on Equity (ttm)

-114.61%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-37.54M
Diluted EPS (ttm)

-0.72

Balance Sheet and Cash Flow

Total Cash (mrq)

43.5M
Total Debt/Equity (mrq)

0.48%
Levered Free Cash Flow (ttm)

-17.65M

COCP Cocrystal Pharma, Inc.

0.9950 +1.53%

TRVI Trevi Therapeutics, Inc.

13.56 -1.81%

VRCA Verrica Pharmaceuticals Inc.

3.3500 -2.05%

FENC Fennec Pharmaceuticals Inc.

10.24 -6.48%

ETON Eton Pharmaceuticals, Inc.

52.18 -2.78%

U.S. markets closed

DiaMedica Therapeutics Inc. (DMAC)

Trading disclosure

6.08%

11.85%

52.89%

16.21%

32.14%

134.18%

-77.48%

DiaMedica Therapeutics Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch